Clinical Trials Epilepsy Events Topical 
The Cannigma
MAY 19, 2021
In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. CBD has become especially trendy in Tokyo, where CBD shops and cafes allow for the on-site consumption of CBD in edibles and topical treatments.
Cannabis Law Report
DECEMBER 20, 2021
(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Virpax is initially seeking FDA approval of its three patented drug delivery platforms. About Altasciences.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Project CBD
FEBRUARY 28, 2023
5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. US Food & Drug Administration website.
Cannabis Law Report
SEPTEMBER 20, 2021
Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis.
Cannabis Law Report
OCTOBER 6, 2021
With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals. Christopher M.
Cannabis Law Report
DECEMBER 8, 2021
Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.
Cannabis Law Report
DECEMBER 28, 2021
We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Epoladerm™ Epoladerm is a diclofenac topical spray film product candidate that is being developed for pain associated with osteoarthritis of the knee. to conduct this study in Canada.
Expert insights. Personalized for you.
137 
Let's personalize your content